Annexin A10 is a marker for the serrated pathway of colorectal carcinoma

Virchows Archiv

Volumn 466, Issue 1, 2015, Pages 5-12

  Sajanti, Sara A ^a,b   Väyrynen, Juha P ^a,b   Sirniö, Päivi ^a,b   Klintrup, Kai ^a,b   Mäkelä, Jyrki ^a,b   Tuomisto, Anne ^a,b   Mäkinen, Markus J ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b MEDICAL RESEARCH CENTER OULU   (Finland)

Author keywords

Annexin A10; BRAF; Colorectal cancer; Immunohistochemistry; Serrated adenocarcinoma

Indexed keywords

ANNEXIN; ANNEXIN A10; B RAF KINASE; UNCLASSIFIED DRUG; VALINE; ANXA10 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADENOMATOUS POLYP; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COLON ADENOMA; COLON POLYP; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HYPERPLASTIC POLYP; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM ADENOMA; SENSITIVITY AND SPECIFICITY; SERRATED ADENOCARCINOMA; TRADITIONAL SERRATED ADENOMA; TUBULOVILLOUS ADENOMA; WILD TYPE; ADENOMA; CASE CONTROL STUDY; COLORECTAL NEOPLASMS; DIFFERENTIAL DIAGNOSIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADENOMA; AGED; ANNEXINS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84925502072     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1683-6     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer Statistics, 2014. CA Cancer J Clin 64:9–29. doi:10.3322/caac.21208
2. O’Brien MJ, Yang S, Huang CS et al (2008) The serrated polyp pathway to colorectal carcinoma. Diagn Histopathol 14:78–93. doi:10.1016/j.mpdhp.2007.12.003
3. Mäkinen MJ, George SM, Jernvall P et al (2001) Colorectal carcinoma associated with serrated adenoma—Prevalence, histological features, and prognosis. J Pathol 193:286–294. doi:10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2
4. Makinen MJ (2007) Colorectal serrated adenocarcinoma. Histopathology 50:131–150. doi:10.1111/j.1365-2559.2006.02548.x
5. Jass JR (2007) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113–130. doi:10.1111/j.1365-2559.2006.02549.x
6. Tuppurainen K, Makinen JM, Junttila O et al (2005) Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol 207:285–294. doi:10.1002/path.1850
7. Snover D, Ahnen D, Burt R, Odze R (2010) Serrated polyps of the colon and rectum and serrated (“hyperplastic”) polyposis. WHO Classif. tumours. Pathol. Genet. Tumours Dig. Syst. Berlin Springer-Verlag (4th Ed)
8. García-Solano J, Pérez-Guillermo M, Conesa-Zamora P et al (2010) Clinicopathologic study of 85 colorectal serrated adenocarcinomas: Further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol 41:1359–1368. doi:10.1016/j.humpath.2010.04.002
9. Kambara T, Simms LA, Whitehall VLJ et al (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53:1137–1144. doi:10.1136/gut.2003.037671
10. O’Brien MJ, Yang S, Mack C et al (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30:1491–1501. doi:10.1097/01.pas.0000213313.36306.85
11. McGivern A, Wynter CV, Whitehall VL et al (2004) Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 3:101–107
12. Poynter JN, Siegmund KD, Weisenberger DJ et al (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17:3208–3215. doi:10.1158/1055-9965.EPI-08-0512
13. Spring KJ, Zhao ZZ, Karamatic R et al (2006) High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 131:1400–1407. doi:10.1053/j.gastro.2006.08.038
14. Burnett-Hartman AN, Newcomb PA, Potter JD et al (2013) Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 73:2863–2872
15. Stefanius K, Ylitalo L, Tuomisto A et al (2011) Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology 58:679–692. doi:10.1111/j.1365-2559.2011.03821.x
16. Sajanti SA, Sirniö P, Väyrynen JP et al (2014) VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. Virchows Arch. doi:10.1007/s00428-014-1555-0
17. Laiho P, Kokko A, Vanharanta S et al (2007) Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 26:312–320. doi:10.1038/sj.onc.1209778
18. Conesa-Zamora P, García-Solano J, García-García F et al (2013) Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. Int J Cancer 132:297–307. doi:10.1002/ijc.27674
19. Mussunoor S, Murray G (2008) The role of annexins in tumour development and progression. J Pathol 216:131–140. doi:10.1002/path
20. Kantola T, Klintrup K, Väyrynen JP et al (2012) Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 107:1729–1736. doi:10.1038/bjc.2012.456
21. Hamilton SR, Bosman FT, Boffetta P et al (2010) Carcinoma of the colon and rectum. In: Bosman F, Carneiro F, Hruban R, Theise N (eds) WHO Classif. tumours Dig. Syst. IARC Press, Lyon, pp 134–146
22. Sobin LH, Wittekind C (2002) TNM classification of malignant tumours. Wiley-Liss, New York
23. Väyrynen JP, Vornanen J, Tervahartiala T et al (2012) Serum MMP-8 levels increase in colorectal cancer and correlate with disease course and inflammatory properties of primary tumors. Int J Cancer 131:E463–E474. doi:10.1002/ijc.26435
24. Väyrynen JP, Sajanti SA, Klintrup K et al (2014) Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer 134:2126–2135. doi:10.1002/ijc.28533
25. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371. doi:10.1152/physrev.00030.2001
26. Duncan R, Carpenter B, Main LC et al (2008) Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98:426–433. doi:10.1038/sj.bjc.6604128
27. Quiskamp N, Poeter M, Raabe CA et al (2014) The tumor suppressor annexin A10 is a novel component of nuclear paraspeckles. Cell Mol Life Sci 71:311–329. doi:10.1007/s00018-013-1375-4
28. Lu S-H, Yuan R-H, Chen Y-L et al (2013) Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system. Histopathology 63:640–648. doi:10.1111/his.12229
29. Kim J, Kim MA, Jee CD et al (2009) Reduced expression and homozygous deletion of annexin A10 in gastric carcinoma. Int J Cancer 125:1842–1850. doi:10.1002/ijc.24541
30. Kim JKYU, Kim PUMJ, Jung KHWA et al (2010) Decreased expression of Annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression. Oncol Rep 24:607–612. doi:10.3892/or
31. Munksgaard PP, Mansilla F, Brems Eskildsen A-S et al (2011) Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 105:1379–1387. doi:10.1038/bjc.2011.404
32. Liu S-H, Lin C-Y, Peng S-Y et al (2002) Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 160:1831–1837. doi:10.1016/S0002-9440(10)61129-7
33. Patsos G, Germann A, Gebert J, Dihlmann S (2010) Restoration of absent in melanoma 2 (AIM2) induces G2/M cell cycle arrest and promotes invasion of colorectal cancer cells. Int J Cancer 126:1838–1849. doi:10.1002/ijc.24905
34. Gonzalo DH, Lai KK, Shadrach B et al (2013) Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol 230:420–429. doi:10.1002/path.4200
35. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290. doi:10.1038/sj.onc.1210421
36. Fearon ER (2011) Molecular genetics of colorectal cancer. Annu Rev Pathol 6:479–507. doi:10.1146/annurev-pathol-011110-130235
37. Shimizu T, Kasamatsu A, Yamamoto A et al (2012) Annexin A10 in human oral cancer: Biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS One 7:e45510. doi:10.1371/journal.pone.0045510
38. Haigis KM, Kendall KR, Wang Y et al (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40:600–608. doi:10.1038/ng.115
39. Rad R, Cadiñanos J, Rad L et al (2013) A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24:15–29. doi:10.1016/j.ccr.2013.05.014
40. Yeh JJ, Routh ED, Rubinas T et al (2009) KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 8:834–843. doi:10.1158/1535-7163.MCT-08-0972